Literature DB >> 25649173

Limited Efficacy of Antibacterial Vaccination Against Secondary Serotype 3 Pneumococcal Pneumonia Following Influenza Infection.

Dennis W Metzger1, Yoichi Furuya1, Sharon L Salmon1, Sean Roberts1, Keer Sun1.   

Abstract

BACKGROUND: Secondary bacterial infections following influenza represent a major cause of mortality in the human population, which, in turn, has led to a call for stockpiling of bacterial vaccines for pandemic preparedness.
METHODS: To investigate the efficacy of bacterial vaccination for protection against secondary pneumococcal infection, mice were immunized with pneumococcal capsular polysaccharide conjugate vaccine, and then sequentially coinfected 5 weeks later with PR8 influenza virus and A66.1 Streptococcus pneumoniae.
RESULTS: In the absence of influenza virus exposure, vaccination with polysaccharide conjugate vaccine was highly effective, as indicated by 100% survival from lethal pneumococcal pneumonia and 10 000-fold greater efficiency in clearance of bacteria from the lung compared to unvaccinated mice. Enhanced clearance after vaccination was dependent upon Fc receptor (FcR) expression. However, following influenza, <40% of vaccinated mice survived bacterial coinfection and FcR-dependent clearance of antibody-opsonized bacteria reduced bacterial levels in the lungs only 5-10 fold. No differences in lung myeloid cell numbers or in FcR cell surface expression were observed following influenza.
CONCLUSIONS: The results show that induction of antibacterial humoral immunity is only partially effective in protection against secondary bacterial infections that occur following influenza, and suggest that additional therapeutic strategies to overcome defective antibacterial immunity should be explored.
© The Author 2015. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  adaptive immunity; coinfection; influenza virus; innate immunity; pneumococcus; pneumonia; vaccination

Mesh:

Substances:

Year:  2015        PMID: 25649173      PMCID: PMC4615793          DOI: 10.1093/infdis/jiv066

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  29 in total

1.  Who Expert Committee on Biological Standardization.

Authors: 
Journal:  World Health Organ Tech Rep Ser       Date:  2005

2.  Pneumococcal vaccines and flu preparedness.

Authors:  Keith P Klugman; Shabir A Madhi
Journal:  Science       Date:  2007-04-06       Impact factor: 47.728

3.  Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: implications for pandemic influenza preparedness.

Authors:  David M Morens; Jeffery K Taubenberger; Anthony S Fauci
Journal:  J Infect Dis       Date:  2008-10-01       Impact factor: 5.226

4.  Fas determines differential fates of resident and recruited macrophages during resolution of acute lung injury.

Authors:  William J Janssen; Lea Barthel; Alaina Muldrow; Rebecca E Oberley-Deegan; Mark T Kearns; Claudia Jakubzick; Peter M Henson
Journal:  Am J Respir Crit Care Med       Date:  2011-09-01       Impact factor: 21.405

Review 5.  Pathology of human influenza revisited.

Authors:  Thijs Kuiken; Jeffery K Taubenberger
Journal:  Vaccine       Date:  2008-09-12       Impact factor: 3.641

6.  Inhibition of pulmonary antibacterial defense by interferon-gamma during recovery from influenza infection.

Authors:  Keer Sun; Dennis W Metzger
Journal:  Nat Med       Date:  2008-04-27       Impact factor: 53.440

7.  Type I IFNs mediate development of postinfluenza bacterial pneumonia in mice.

Authors:  Arash Shahangian; Edward K Chow; Xiaoli Tian; Jason R Kang; Amir Ghaffari; Su Y Liu; John A Belperio; Genhong Cheng; Jane C Deng
Journal:  J Clin Invest       Date:  2009-07       Impact factor: 14.808

8.  Lowering the threshold of lung innate immune cell activation alters susceptibility to secondary bacterial superinfection.

Authors:  John Goulding; Alexandra Godlee; Seema Vekaria; Markus Hilty; Robert Snelgrove; Tracy Hussell
Journal:  J Infect Dis       Date:  2011-10-01       Impact factor: 5.226

9.  Type I interferon signaling regulates Ly6C(hi) monocytes and neutrophils during acute viral pneumonia in mice.

Authors:  Sang-Uk Seo; Hyung-Joon Kwon; Hyun-Jeong Ko; Young-Ho Byun; Baik Lin Seong; Satoshi Uematsu; Shizuo Akira; Mi-Na Kweon
Journal:  PLoS Pathog       Date:  2011-02-24       Impact factor: 6.823

10.  Sustained desensitization to bacterial Toll-like receptor ligands after resolution of respiratory influenza infection.

Authors:  Arnaud Didierlaurent; John Goulding; Seema Patel; Robert Snelgrove; Lionel Low; Magali Bebien; Toby Lawrence; Leonie S van Rijt; Bart N Lambrecht; Jean-Claude Sirard; Tracy Hussell
Journal:  J Exp Med       Date:  2008-01-28       Impact factor: 14.307

View more
  17 in total

1.  Defective anti-polysaccharide IgG vaccine responses in IgA deficient mice.

Authors:  Yoichi Furuya; Girish S Kirimanjeswara; Sean Roberts; Rachael Racine; Jennifer Wilson-Welder; Alan M Sanfilippo; Sharon L Salmon; Dennis W Metzger
Journal:  Vaccine       Date:  2017-07-31       Impact factor: 3.641

Review 2.  The Unexpected Impact of Vaccines on Secondary Bacterial Infections Following Influenza.

Authors:  Amber M Smith; Victor C Huber
Journal:  Viral Immunol       Date:  2017-11-17       Impact factor: 2.257

3.  Lethal synergy between SARS-CoV-2 and Streptococcus pneumoniae in hACE2 mice and protective efficacy of vaccination.

Authors:  Tarani Kanta Barman; Amit K Singh; Jesse L Bonin; Tanvir Noor Nafiz; Sharon L Salmon; Dennis W Metzger
Journal:  JCI Insight       Date:  2022-06-08

4.  Lethal Synergism between Influenza and Streptococcus pneumoniae.

Authors:  Jennifer M Rudd; Harshini K Ashar; Vincent Tk Chow; Narasaraju Teluguakula
Journal:  J Infect Pulm Dis       Date:  2016-04-30

5.  A Perfect Storm: Increased Colonization and Failure of Vaccination Leads to Severe Secondary Bacterial Infection in Influenza Virus-Infected Obese Mice.

Authors:  Erik A Karlsson; Victoria A Meliopoulos; Nicholas C van de Velde; Lee-Ann van de Velde; Beth Mann; Geli Gao; Jason Rosch; Elaine Tuomanen; Jon McCullers; Peter Vogel; Stacey Schultz-Cherry
Journal:  mBio       Date:  2017-09-19       Impact factor: 7.867

6.  Interleukin-4 protects mice against lethal influenza and Streptococcus pneumoniae co-infected pneumonia.

Authors:  Yang Peng; Xiaofang Wang; Hong Wang; Wenchun Xu; Kaifeng Wu; Xuemei Go; Yibing Yin; Xuemei Zhang
Journal:  Clin Exp Immunol       Date:  2021-07-07       Impact factor: 5.732

Review 7.  The Association between Invasive Group A Streptococcal Diseases and Viral Respiratory Tract Infections.

Authors:  Andrea L Herrera; Victor C Huber; Michael S Chaussee
Journal:  Front Microbiol       Date:  2016-03-21       Impact factor: 5.640

8.  Impaired expression of CXCL5 and matrix metalloproteinases in the lungs of mice with high susceptibility to Streptococcus pneumoniae infection.

Authors:  Rubia I Mancuso; Eliane N Miyaji; Cristiane C F Silva; Fernanda V Portaro; Alessandra Soares-Schanoski; Orlando G Ribeiro; Maria Leonor S Oliveira
Journal:  Immun Inflamm Dis       Date:  2017-11-09

9.  Quantifying the therapeutic requirements and potential for combination therapy to prevent bacterial coinfection during influenza.

Authors:  Amber M Smith
Journal:  J Pharmacokinet Pharmacodyn       Date:  2016-09-27       Impact factor: 2.745

10.  Impact of Influenza on Pneumococcal Vaccine Effectiveness during Streptococcus pneumoniae Infection in Aged Murine Lung.

Authors:  Ermias Jirru; Stefi Lee; Rebecca Harris; Jianjun Yang; Soo Jung Cho; Heather Stout-Delgado
Journal:  Vaccines (Basel)       Date:  2020-06-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.